• A commercial cell separation system (C-SVF) yields viable SVF cells comparable to laboratory enzymatic digestion, with enhanced proliferation and reduced apoptosis in vitro.
• In a mouse wound model, C-SVF significantly accelerates wound closure, improves collagen remodeling, and promotes angiogenesis.
• Single-nucleus RNA sequencing reveals that C-SVF is enriched with APOE+ adipose-derived stem cells and M2 anti-inflammatory macrophages, which jointly drive wound repair.
• The commercial extraction system offers an effective, clinically viable method for isolating therapeutic SVF cells, potentially improving regenerative therapy outcomes.